Ipamorelin

IPA

Growth Hormone

CAS

170851-70-4

Molecular Weight

711

Da

Animal Only

A selective synthetic peptide that stimulates growth hormone release from the pituitary gland without significantly affecting cortisol or prolactin. One of the most popular peptides in longevity and performance protocols due to its clean hormonal profile. Has reached human clinical trials. Often combined with CJC-1295 for amplified effect.

Injectable

Intranasal Suitable

Yes

Research Compound

Research Quality Score
7 dimensions · 100 points total · Methodology by PeptideClear
35/100
Weak Evidence
Study Design
6/25
Sample Size
4/20
Replication
10/20
Journal Impact Factor
8/15
Funding Independence
4/10
Population Diversity
0/5
Researcher h-Index
3/5
Dimension Breakdown
Study DesignQuality of research methodology — RCT, observational, animal, or in vitro
6/ 25
Sample SizeNumber of participants across studies supporting this compound
4/ 20
ReplicationIndependent reproduction of findings by separate research groups
10/ 20
Journal Impact FactorPrestige of journals where primary studies were published
8/ 15
Funding IndependenceDegree to which research was funded independently of industry
4/ 10
Population DiversityDiversity of study participants across age, sex, and ethnicity
0/ 5
Researcher h-IndexCitation credibility of the primary research team
3/ 5
⚠️

Animal evidence note: Score reflects current human evidence. Animal evidence may be stronger than the total score indicates — this compound has not yet been studied in human trials.

Scored by PeptideClear editorial team · Based on publicly available literature
StrongModerateLimitedWeak

Community Signal

Community signal is generally positive but methodologically murky. Ipamorelin is almost universally discussed in combination with CJC-1295 rather than as a standalone compound, making isolated attribution nearly impossible. The CJC/Ipa stack is one of the most commonly referenced peptide combinations in biohacking forums. Sleep quality, recovery, and mild body composition changes are the most frequently cited benefits. Side effect reports are notably rare compared to other GH secretagogues, which the community attributes to its GH-specific mechanism without cortisol or prolactin elevation. Dosing timing debates, pre-bed vs pre-workout, are a recurring community discussion.

We break down one compound like this every week

The Honest Dose — free, no sponsorships, no agenda. Just the evidence.

Subscribe free →

What It Is

Ipamorelin is a synthetic pentapeptide — a chain of five amino acids — and a selective growth hormone secretagogue. Unlike other peptides in its class, ipamorelin stimulates growth hormone release with high selectivity, meaning it triggers GH release without significantly affecting other hormones like cortisol or prolactin. It was originally developed by Novo Nordisk in the 1990s and reached Phase II clinical trials before development was discontinued for commercial reasons unrelated to safety.

Mechanism of Action

Ipamorelin works by mimicking ghrelin and binding to the ghrelin receptor (GHS-R1a) in the pituitary gland, stimulating a pulse of growth hormone release. What distinguishes it from other growth hormone secretagogues like GHRP-2 or GHRP-6 is its selectivity — it produces a clean GH pulse without the appetite stimulation, cortisol spike, or prolactin elevation associated with less selective peptides. It is often combined with a GHRH (Growth Hormone Releasing Hormone) analog like CJC-1295 to amplify and extend the GH pulse.

Use Cases

Ipamorelin is studied and used for stimulating growth hormone production, supporting lean muscle development, improving sleep quality (GH is predominantly released during deep sleep), fat metabolism, and anti-aging protocols. It is one of the most popular peptides in the longevity and performance community due to its clean hormonal profile relative to other GH secretagogues.

Known Risks

While ipamorelin has a relatively favorable safety profile compared to other GH secretagogues, considerations include: potential suppression of natural GH axis with prolonged use, water retention, tingling or numbness at injection sites, and headaches particularly during initial use. Individuals with active malignancies should avoid GH-stimulating peptides as growth hormone can theoretically accelerate tumor growth. Not recommended during pregnancy or breastfeeding. Long-term effects in humans are not well established.

Available Forms

Injectable (subcutaneous). Typically sold as a lyophilized powder requiring reconstitution with bacteriostatic water. Some oral and nasal formulations exist but bioavailability data is limited and injectable remains the standard form used in research and clinical compounding contexts.

Regulatory Status

Ipamorelin is not FDA approved as a standalone drug. However it has been used in licensed compounding pharmacies as a prescription compound, making it one of the more accessible peptides through legitimate clinical channels. Its status in compounding has faced increasing scrutiny — it was added to the FDA's list of difficult to compound drugs in recent years. Consult a licensed provider for current prescribing status in your jurisdiction.

Sources

https://pubmed.ncbi.nlm.nih.gov/9849822/

https://pubmed.ncbi.nlm.nih.gov/10373343/

https://pubmed.ncbi.nlm.nih.gov/9467542/

Similar Compounds

Sermorelin, CJC-1295, GHRP-2, BPC-157

Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.

Join The Honest Dose →

Last Reviewed